scholarly article | Q13442814 |
P50 | author | Larisa Gubareva | Q66732793 |
Frederick G Hayden | Q87843428 | ||
Thomas J Braciale | Q92204271 | ||
Vasiliy P Mishin | Q104774731 | ||
P2093 | author name string | Michael G Ison | |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | oseltamivir | Q211509 |
murine model | Q122890741 | ||
P1104 | number of pages | 8 | |
P304 | page(s) | 765-772 | |
P577 | publication date | 2006-02-13 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection | |
P478 | volume | 193 |
Q45325322 | A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment |
Q42111794 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice |
Q37379466 | Animal models for the study of influenza pathogenesis and therapy |
Q58066873 | Anti-influenza therapy: the emerging challenge of resistance |
Q64901554 | Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. |
Q30394067 | Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses |
Q43731586 | Children with cancer and respiratory viral infection: epidemiology, diagnosis and treatment options |
Q58614971 | Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus |
Q30414428 | Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice |
Q38268152 | Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo |
Q35758840 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus |
Q35860081 | Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates. |
Q41933615 | Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques |
Q34597005 | Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. |
Q37857854 | Influenza pharmacotherapy: present situation, strategies and hopes |
Q36845779 | Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site. |
Q30364868 | Molecular determinants of influenza virus pathogenesis in mice. |
Q30456363 | Newer influenza antivirals, biotherapeutics and combinations |
Q34020714 | Oseltamivir treatment prevents the increased influenza virus disease severity and lethality occurring in chronic ethanol consuming mice |
Q39092470 | Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil |
Q47593385 | Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system |
Q40094068 | Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection |
Q37204154 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system |
Q39168195 | Recent advances in the Overman rearrangement: synthesis of natural products and valuable compounds. |
Q30392198 | Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice |
Q30359363 | Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. |
Q37696588 | The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome |
Q37618653 | The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures |
Q30364977 | The role of oseltamivir in the treatment and prevention of influenza in children. |
Q43873120 | Viral loads and duration of viral shedding in adult patients hospitalized with influenza. |
Search more.